

1 **Systematic druggable genome-wide Mendelian randomization identifies** 2 **therapeutic target genes for chronic periodontitis**

3 Zhongwei Cheng^{1#}, Fang Wang^{1#}, Meimei Ran^{3‡}, Shenhu Liang^{2‡}, Qinggao Song^{1*}

4
5 1 Department of Oral and Maxillofacial Surgery Affiliated Stomatological Hospital of Zunyi
6 Medical University, Zunyi, Guizhou, China.

7 2 School and Hospital of Stomatology, Zunyi Medical University, Zunyi, Guizhou, China.

8 3 Information Technology Network Management Center, Zunyi Medical And Pharmaceutical
9 College, Zunyi, Guizhou, China.

10

11 # These authors contributed equally to this work.

12 ‡ These authors also contributed equally to this work.

13 *Correspondence: Qinggao Song (814641639@qq.com)

14

15 **Abstract**

16 Currently, the treatment of chronic periodontitis (CP) still has challenges. This study aimed to
17 identify novel drug targets for the treatment of chronic periodontitis in the druggable genome
18 using the Mendelian randomization (MR) method. In this study, based on the list of 4479 drug gene
19 targets, overlapping genes were selected in blood expression Quantitative Trait Loci (eQTL), which
20 were then subjected to Two-Sample MR (TSMR) and validated Fusion Transcriptome-Wide
21 Association Study (TWAS) with data from the Genome-Wide Association Study (GWAS) of CP to
22 confirm drug genes genetically associated with CP and tested for multiplicity of effects using
23 Summary-data-based Mendelian randomization (SMR) analysis and colocalisation. Finally,
24 Phenome-Wide association study (PheWAS) was executed on the identified drug targets. We
25 applied SMR, TSMR, Fusion TWAS, and a series of manners of co-localisation to assess the genetic
26 association between druggable targets and CP. In conclusion, Metalloproteinase 25 (MMP25) was
27 considered the most promising drug target, in addition to which we maintained some confidence in
28 TNFRSF18, CDC25B, STK10 and ACVR2B. Finally, the PheWAS-MR results showed that the
29 possible side effects of applying MMP25 inhibitors were Otitis externa as well as some metabolic
30 disorders, among others. In summary, we identified five potential CP drug targets using
31 TSMR, Fusion TWAS, SMR, and co-localisation a series of methods, of which MMP25 passed all
32 the tests. Such discovery offered an academic basis for future CP drug development and reduce
33 drug development time and economic costs to some extent.

34 **Keywords: Chronic periodontitis, Genome-wide Mendelian randomisation, Target genes.**

35

36 **Introduction**

37 Periodontitis affects approximately 70-80% of adults and is the sixth most epidemic illness around
38 the world [1], it causes severe inflammation in the tissues surrounding teeth, such as gums,
39 alveolar bone and periodontal ligament, which, in addition to the tooth loss, bone loss, and
40 formation of periodontal pockets [2,3], is also closely associated with a number of systemic
41 illness, such as diabetes mellitus, cardiovascular disease, and chronic kidney disease [4-7]. The
42 persistent progression of gingival recession in chronic periodontitis (CP) severely reduces the
43 patients' life quality and brings social health organisations a great challenge [1]. In fact, the

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 pathogenesis of chronic periodontitis is complex and multifactorial, and although microbial
45 infection of the periodontal biofilm is the main etiological factor, it is also largely related to a
46 combination of host autoimmune characteristics, environmental factors, and genetic
47 susceptibility[8-10], which makes it difficult to treat chronic periodontitis effectively.

48 Previous studies have shown that anti-cytokine therapy (inhibition of tumour necrosis factor,
49 interleukin-1 or interleukin-17 action) has demonstrated some efficacy in experimental models of
50 periodontitis [11] and several clinical studies have evaluated antirheumatic drugs (anabolic acid,
51 etanercept and infliximab, among others) and NSAIDs as having a positive effect on periodontitis
52 [12]. In addition, Amyndas Pharmaceuticals approved the development of new drugs (e.g.
53 improved analogues of the C3 inhibitor conistatin family, i.e. Cp40) , which set the stage for the
54 progression of AMY-101 [13-15]. However, in host regulation therapies, there may be potential
55 safety problems involving biological targeting specific components of the immune response,
56 includes the infection risk increased, especially with the long-term use of NSAIDs, where the
57 possibility of ill effects and unknown hazards is greater [9][16,17]. Therefore, there is a need to
58 continue to explore potential therapeutic gene targets for CP therapy.

59 Mendelian randomization (MR) has been used in various fields of medicine as an effective
60 method to speculate causality between two phenotypes by genetic variants as instrumental
61 variables (IVs) [18]. In addition MR analysis can be used to find new drug targets by
62 consolidating pooled data from illness genome-wide association studies (GWAS) and expression
63 quantitative trait loci (eQTL) researchs [19]. In druggable genes' genomic regions, eQTLs was
64 found to represent characterising traits, as the level of gene expression could be viewed as a kind
65 of lifelong exposure [20]. So we conducted a scientific genome-wide MR study to search possible
66 targets for chronic periodontitis treatment. Firstly, we screened cis-eQTLs from blood eQTLs
67 through information of drug genes list. Using GWAS data of chronic periodontitis, two-sample
68 MR analysis was taken to identify genes highly related to chronic periodontitis. Then we
69 performed SMR analysis, co-localisation analysis, and TWAS analysis to prove the robustness of
70 the MR results. Phenome-wide association study (PheWAS) was then performed on the identified
71 drug targets.

72

73 **Materials and methods**

74 Our study design process is shown in Fig1. The following is a detailed description of the methods
75 and materials used in this study.

76

77 **Figure 1. Flowchart of the design of this study.** MAF: Minor allele frequency; eQTL: Expression quantitative
78 trait loci; SMR: Summary-data-based Mendelian randomization; GWAS: Genome-wide association Studies;
79 TWAS: Transcriptome-wide association analysis; PheWAS: Phenome-wide association study.

80 **Source of druggable gene targets**

81 In order to be able to provide a comprehensive and credible list of druggable gene targets for
82 subsequent studies, we selected a list of 4,479 druggable genes (20,300 protein-coding genes
83 annotated in Ensembl v.73) consolidated by Finan C, et al [21], which has 31.9% (1,427/4479) of
84 genes with approved or clinical-stage drug targets, 15.2% (689/4479) of the genes are similar to
85 approved drug targets and 52.9% (2370/4479) encode proteins that are remotely similar to
86 approved drug targets, which are widely used in many studies today [22]. Information of
87 druggable genes on the list comes from the original article's publicly available supplementary

88 material.

89 **Chronic periodontitis GWAS data and eQTL dataset GWAS data sources**

90 The raw eQTL public data downloaded from the official eQTLGen (<https://eqtlgen.org/>) website
91 [23], which summarises cis-eQTL for 16,987 genes (318,614 blood samples from healthy
92 individuals of European descent), and the current study only included samples from this raw
93 dataset with false discovery rate (FDR) < 0.05 in this original dataset.

94 Chronic periodontitis GWAS data were obtained from the Finnish database version R11
95 (updated 24 June 2024), which includes 5,364 cases and 288,472 controls of European origin, in
96 the Finnish database under the category ‘Diseases of the digestive system’. The phenotype
97 ‘Chronic periodontitis’ was searched in the Finnish database under the category ‘Diseases of the
98 digestive system’ and was downloaded with reference to ICD-10:K05.30 and K05.31 or
99 ICD-9/ICD-8:5234 for inclusion criteria [24]. And various genetic principal components were
100 adjusted (age, sex, and 20 others). In this study, data were downloaded from public databases or
101 official websites, all original studies involved have received ethical approval, and the ethical
102 committee approval was not required for this particular aspect of the study.

103 **Screening of instrumental variable**

104 In this study, SNPs with overlapping druggable genes transcriptional start site (TSS) \pm 100KB
105 were extracted from the eQTL dataset as instrumental variables based on the list of druggable
106 genes. Additionally three key assumptions had to be met for MR causal inference. i):IVs must
107 have evidence of characterised exposure, therefore a genome-wide significance threshold (5×10^{-8})
108 and the linkage disequilibrium (LD) threshold $R^2 < 0.1$ were set in this study (based on 1,000
109 Genomes Project European population) to screen eligible IVs and excluded weak instrumental
110 variables with F-statistics less than 10 [25]; ii):IVs must not be associated with confounders of
111 chronic periodontitis; and iii) IVs must pass the test of horizontal pleiotropy [26-27].

112 **Statistical analysis**

113 For MR inference methods there are several to pick from; when the number of IVs characterising
114 the exposure is 1, the Wald ratio is chosen as the appropriate method for causal inference [28];
115 when the number of IVs is greater than or equal to 2, the IVW method with strong statistical
116 validity is chosen. the OR calculation relies on the Wald ratio method [29] and the delta method
117 assesses the corresponding 95% confidence interval. In addition to this, we coordinated the
118 exposure and outcome data according to the effect and non-effect alleles of each SNP. SNPs with
119 allelic mismatches were excluded to ensure data integrity. Finally, FDR was used to adjust for type
120 I errors from multiple hypothesis testing (PFDR < 0.05) [30].

121 **Multiple validity testing**

122 Since the IVs used in this MR study originated from single-gene regions, multiple gene region
123 pleiotropy detection methods (e.g., MR-Egger intercept) were no longer applicable, and we used
124 summary-data-based Mendelian randomisation (SMR) and Bayesian co-localisation to complete
125 the single-gene region horizontal pleiotropy association detection, where SMR was combined with
126 Heterogeneity In Dependence Instrumental Variables (HEIDI) to detect heterogeneity in the results
127 [31]. In addition co-localisation of five mutually exclusive models corresponding to five posterior
128 probabilities [32]: PPH0-PPH4. In this study, co-localisation analyses were performed using SNPs
129 within ± 100 kb of the TSS of each gene in the eQTL and concluded that the genetic association
130 between the expression level of the gene and the risk of chronic periodontitis was supported by the
131 colocalisation when $PPH4 \geq 0.6$.

132 **TWAS Validation**

133 FUSION Transcriptome-Wide Association Study (TWAS) analyses are used to predict and test the
134 correlation between gene expression and specific diseases or phenotypes by combining aggregated
135 GWAS statistics with gene expression data, which can be used to predict and test the correlation
136 between gene expression and specific diseases or phenotypes by identifying genes that are
137 significantly correlated with complex traits in individuals who do not have direct measurements of
138 their expression levels, to provide a more comprehensive understanding of the genetic
139 mechanisms of disease and guide future drug development and therapeutic strategies [33-34].
140 Download the code on Git-hub, containing the relevant code for mapping and making weight files
141 (https://github.com/gusevlab/fusion_twass). top1, blup, lasso, enet, and bs1mm are the five
142 prediction models used by FUSION, and we applied FUSION to correlate CP's genetic effects
143 with eQTL weights to calculate the linear product of Z-values of SNPs and eQTL weights for
144 TWAS analysis.

145 **Phenome-wide association study**

146 In order to assess the potential side effects of the identified drug targets, we performed
147 PheWAS-MR (<https://www.leelabsg.org/resources>) on selected phenotype-wide GWAS data (779
148 in total) from UK Biobank. The original database was adjusted for sample case-control imbalance
149 with cryptic relatedness using the Scalable and Accurate Implementation of Generalised mixed
150 model (SAIGE) (V.0.29) method to account for unbalanced of the case-control ratio [35]. In
151 addition to this, the IVs screening strategy was harmonised with the above and the IVW method
152 was used as the primary method, with MR Egger, Weighted median and Weighted mode as the
153 secondary methods for PheWAS-MR. Finally the FDR (BH) was used to correct for the multiple
154 test results, and a PFDR < 0.05 was considered as the threshold of significance.

155

156 **Results**

157 Selected according to the set screening criteria, this study extracted 2288 genes from the eQTL
158 dataset, corresponding to 27,496 IVs, (F-statistics ranging from 29.7-3450.7), and detailed
159 information of the IVs is shown in **Additional Table 1**.

160 This study ultimately investigated the genetic association of 2288 potential drug genes with
161 CP using MR (**Additional Table 2**), and after FDR correction, 13 genes were found to be
162 genetically associated with CP (**Fig. 2A and Fig. 2B**), including matrix metalloproteinase 25
163 (MMP25) [odds ratio (OR)=1.13, 95% CI: 1.07-1.19, $P = 1.45 \times 10^{-5}$], proteasome 20S subunit
164 alpha 4 (PSMA4) (OR = 1.39, 95% CI: 1.19-1.62, $P = 2.74 \times 10^{-5}$) and muscleblind like splicing
165 regulator 1 (MBNL1) (OR=1.17, 95% CI: 1.08-1.26, $P = 3.70 \times 10^{-5}$) and seven other drug gene
166 expression levels were positively correlated with CP, whereas the expression levels of TNF
167 receptor superfamily member 18 (TNFRSF18) (OR=0.81, 95% CI: 0.73-0.89, $P = 2.01 \times 10^{-5}$),
168 serine/threonine kinase 10 (STK10) (OR = 0.78, 95% CI: 0.69-0.89, $P = 1.02 \times 10^{-4}$) and activin A
169 receptor type 2B (ACVR2B) (OR = 0.85, 95% CI: 0.79-0.93, $P = 1.21 \times 10^{-4}$) and eight other
170 drug gene expression levels were negatively correlated with CP.

171

172 **Figure 2. Mendelian randomisation results of druggable genes with CP.** A: Volcano plot of MR results. The
173 size of the dots represents the size of PVE, and the purple dotted line indicates the threshold after FDR<0.05
174 correction. PVE: proportion of variance explained; $PVE = \frac{\sum(\beta \cdot exposure^2)}{\sum(\beta \cdot exposure^2 +$
175 $sample \cdot se \cdot exposure^2)}$. B: Forest plot of MR results.

176 Multiplicity testing showed that only MMP25 was supported by SMR&HEIDI results and
177 co-localisation results, and passed the validated Fusion TWAS test. In addition, TNFRSF18, cell
178 division cycle 25B (CDC25B), STK10, and ACVR2B passed the SMR&HEIDI and validated
179 Fusion TWAS tests, but were not supported by co-localisation results (see **Table 1** for detailed
180 results). Unfortunately, PSMA4 and ADAM10 only passed the validated Fusion TWAS test.

181 Then, based on the MR, SMR&HEIDI, co-localisation and validated Fusion TWAS test
182 results, we assigned endorsement grades to CP-associated pharmacogenes, among which we
183 maintained the highest confidence in MMP25, as the MR, SMR&HEIDI, co-localisation, and
184 validated Fusion TWAS test results all provided sufficient evidence of genetic linkage with CP
185 genetic association. We also maintained some confidence in TNFRSF18, CDC25B, STK10, and
186 ACVR2B as they passed MR, SMR&HEIDI, and validated Fusion TWAS test results, and just
187 failed co-localisation, which may be due to the low number of risk loci in the raw GWAS data for
188 CP. We had lower confidence in eight drug genes such as PSMA4, ADAM10 and NKTR.

189 Finally, since drugs usually act via blood circulation, we used PheWAS-MR to evaluate the
190 potential side effects of MMP25 as a drug target (**Fig. 3**). IVW results showed (FDR<0.05),
191 MMP25 was associated with 19 phenotypes (**Additional Table 3**), where MMP25 was the
192 Premature beats (OR=1.472 (OR=1.472, P=3.77×10⁻⁶), Dizziness and giddiness (OR=1.74,
193 P=6.97×10⁻⁶) and Type 2 diabetes with neurological manifestations (OR=1.39, P=9.91×10⁻⁶) were
194 13 phenotypic risk Factors. In contrast, MMP25 was a risk factor for Otitis externa (OR=0.717,
195 P=2.42×10⁻⁵), Other disorders of metabolism (OR=0.834, P=1.41×10⁻⁴) and Cellulitis and abscess
196 of trunk (OR=0.733, P=2.68×10⁻⁴) and other protective factors for six phenotypes.

197 The main statistical analysis was performed in R (version 4.3.3). Using the "coloc" software
198 package (version 5.2.1) for Bayesian colocation analysis, Two-sample MR analysis was conducted
199 with "MendelianRandomization" (version 0.6.6). SMR analysis from
200 <https://yanglab.westlake.edu.cn/software/smr/#Download>. TWAS analysis code from
201 <https://github.com/DelinLi/TWAS>.

202

203 **Table 1. Results of colocalization, SMR and TWAS analysis.**

Gene	IVW_pval (FDR)	SMR_pval	HEIDI_pval	TWAS_pval	Co-localization analysis
MMP25	0.019	0.002	0.731	7.71×10 ⁻⁵	0.627
TNFRSF18	0.019	0.046	0.855	0.018	0.039
PSMA4	0.019	2.88×10 ⁻³	0.040	0.002	NA
MBNL1	0.019	0.034	0.545	NA	NA
CDC25B	0.019	0.036	0.502	0.011	0.022
BLK	0.024	0.309	0.102	0.325	NA
ALPL	0.026	0.027	0.086	NA	NA
ADAM10	0.026	0.141	0.709	0.035	NA
STK10	0.026	0.038	0.774	0.015	0.091
ACVR2B	0.028	0.034	0.195	0.032	0.07
NKTR	0.038	0.006	0.237	0.496	NA
KLHL3	0.038	0.208	0.987	NA	NA
GSTA4	0.038	0.002	0.648	NA	NA

204 Note:IVW,inverse variance weighted;SMR,Summary-data-based Mendelian randomization;HEIDI,Heterogeneity

205 In Dependence Instrumental Variables; TWAS, Transcriptome-Wide Association Study.

206

207 **Discussion**

208 This study used TSMR, Fusion TWAS, SMR, and co-localisation a range of methods to assess the
209 genetic association between druggable targets and CP. In conclusion, MMP25 passed all the tests
210 and therefore we maintain maximum confidence in it, in addition to TNFRSF18, CDC25B,
211 STK10 and ACVR2B. Finally, we investigated the potential side effects of MMP25 as a target
212 using PheWAS-MR.

213 MMP25 is an enzyme belonging to the MMP family. MMP participates in many
214 physiological processes and is a group of highly conserved endopeptidases [36-37]. Numerous
215 researches have indicated that the MMP family was vital in driving inflammation in periodontitis,
216 promoting periodontal tissue destruction through degradation and remodelling of extracellular
217 matrix components. Some in vitro experiments verified that the pathogenic bacterium causing CP
218 (*Fusarium nucleatum*) promotes further inflammation in periodontal tissues, including alveolar
219 bone resorption and cellular matrix degradation, by stimulating macrophages to increase the
220 secretion of MMP9 [38]. It has been demonstrated that there may be a positive feedback loop
221 between MMP13 and MMP9, which together promote periodontal tissue inflammation and bone
222 loss [39]. Initially, it was found that MMP25 was specifically expressed in peripheral blood
223 leukocytes and upregulated in mouse models of cancer and infection, and the close relationship
224 with periodontitis has been repeatedly demonstrated, for example, a randomised controlled trial
225 found that MMP25 levels in gingival sulcus fluid of patients with chronic periodontitis were
226 higher than in healthy controls [40]. Another basic study found that levels of MMP25 in
227 periodontal tissues of chronic periodontitis increased. In conclusion, MMP25 is closely related to
228 chronic periodontitis, which is consistent with the conclusions reached in the current study [41].

229

230 **Figure 3. Results of MR studies of the full phenotypic range of MMP25.**

231 TNFRSF18 is also referred to as Glucocorticoid-Induced TNFR-Related protein (GITR),
232 which has been linked to immune system homeostasis and inflammatory disease development.
233 Currently, although there are no direct studies on TNFRSF18 and CP, it has been reported that a
234 TNFRSF member, TNFSF14, was important in promoting the CXCL10 secretion and CXCL11
235 from human gingival fibroblasts, the infiltration of Th1 cells into foci of inflammatory illness can
236 be promoted, and was a prospective target for periodontitis treatment.

237 STK10 gene belongs to Ste20 family and encodes a serine/threonine protein kinase. The
238 protein binds to and phosphorylates polo-like kinase 1, its kinase-dead overexpression disturbs
239 cell cycle progression [42-43]; CDC25B belongs to phosphatases CDC25 family, and is necessary
240 for cells to enter mitosis [44]; ACVR2B acts as a signalling mediator with the ability to transmit
241 activin signals that regulate many pathological and physiological processes [45-46]. STK10,
242 CDC25B and ACVR2B have been little studied in CP, so further experiments are needed to verify
243 their association with CP.

244 In this study, we used many effective methods to improve the robustness of the MR study;
245 firstly: the included instrumental variables all have F-statistics greater than 10, so they have the
246 ability to characterise the drug genes; secondly, in order to unify the genomic co-ordinates, we
247 localised the current MR study using SNPs to the human genome HG19/GRCh37; thirdly, we
248 used Fusion TWAS to enhance the association between the drug association between genes and

249 CP; fourth, all GWAS data were from European ethnicity to reduce genetic confounding due to
250 ethnic differences; fifth, we selected only SNPs within the cis-eqtl region and used SMR and
251 co-localisation to avoid horizontal pleiotropy.

252 There are still limitations in this study. First, although MR verified the causal relationship
253 between drug gene targets and CP genetically via the IV method, the MR approach assumes a
254 linear relationship between CP and drug gene expression levels. Therefore, MR results should be
255 viewed with caution in case of nonlinear correlation between outcome and exposure. Secondly,
256 the GWAS data of the current study on the association between drug genes and CP were obtained
257 from people of European descent. Therefore, the MR results need to be further investigated and
258 validated when extended to other ethnic groups to ensure wider applicability. Thirdly, this study
259 only concentrated on the causality between the pharmacogenetic cis-eQTL and CP, and lacked the
260 study of trans-eQTL. Finally, the results of this study need to be supported by clinical data, which
261 is also the direction of our future efforts.

262

263 **Conclusion**

264 Five potential CP drug targets were identified in this study using TSMR, Fusion TWAS, SMR,
265 and a series of co-localisation methods, of which MMP25 passed all the tests, so we maintain the
266 utmost confidence in it. The findings provide a rationale for future CP drug development and
267 reduce the cost of drug development to some extent.

268

269 **Supporting information**

270 S1 Fig.Flowchart of the design of this study.

271 S2 Fig.Mendelian randomisation results of druggable genes with CP.

272 S3 Fig.Results of MR studies of the full phenotypic range of MMP25.

273 S1 Table. Details of extracted instrumental variables.

274 S2 Table.MR results.

275 S3 Table.PheWAS-MR results.

276 S1 Checklist.STROBE-MR-checklist.

277

278 **Acknowledgments**

279 This study would like to thank the official eQTLGen (<https://eqtlgen.org/>) website and the Finnish
280 database version R11 (<https://www.finngen.fi/fi>) and public catalog GWAS data provided.Thanks
281 to all authors for their contributions.

282

283 **Author Contributions**

284 **Data curation:**Zhong-wei Cheng,Fang Wang,Shen-hu Liang.

285 **Formal analysis:**Zhong-wei Cheng,Fang Wang,Qing-gao Song.

286 **Project administration:**Qing-gao Song.

287 **Software:**Mei-mei Ran.

288 **Supervision:**Shen-hu Liang.

289 **Writing – original draft:**Zhong-wei Cheng.

290

291 **Funding information**

292 This research was supported by grants from the Zunyi United Fund: Innovative Team in Oral and

293 Maxillofacial Plastic Surgery (Code: Zunyi Science Cooperation HZ No. (2020) 294) and the
294 Zunyi Science and Technology Programme Funded Project (Nos. Zunyi Joint Fund,
295 HZ2023-464).The funders had no role in study design,data collection and analysis,decision to
296 publish,or preparation of the manuscript.

297

298 **Conflicts of Interest statement**

299 The authors declared no potential conflicts of interest with respect to the research, authorship,
300 and/or publication of this article.

301

302 **Data availability statement**

303 All data included in this study are available upon request through contact with the corresponding
304 author.

305

306 **Ethics statement**

307 In this study, data were downloaded from public databases or official websites, all original studies
308 involved have received ethical approval.

309


310 **References**

- 311 [1] Eke PI, Thornton-Evans GO, Wei L, Borgnakke WS, Dye BA. (2018).Genco RJ.
312 Periodontitis in US Adults: National Health and Nutrition Examination Survey 2009-2014. Journal
313 of the American Dental Association, 149(7):576-588.e6. doi: 10.1016/j.adaj.2018.04.023.
- 314 [2] Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J.(2017) Impact of the global burden of
315 periodontal diseases on health, nutrition and wellbeing of mankind: A call for global action.
316 Journal of Clinical Periodontology, 44(5):456-462. doi: 10.1111/jcpe.12732.
- 317 [3] Smith MM, Knight ET, Al-Harhi L, Leichter JW.(2017) Chronic periodontitis and implant
318 dentistry. Periodontol 2000, 74(1):63-73. doi: 10.1111/prd.12190.
- 319 [4] Parsegian K, Randall D, Curtis M, Ioannidou E.(2022) Association between periodontitis and
320 chronic kidney disease. Periodontol 2000,89(1):114-124. doi: 10.1111/prd.12431.
- 321 [5] Kavarthapu A, Gurumoorthy K.(2021) Linking chronic periodontitis and oral cancer: A
322 review. Oral Oncology, 121:105375. doi: 10.1016/j.oraloncology.2021.105375.
- 323 [6] Li S, Li H, Kong H, Wu SY, Cheng CK, Xu J.(2023) Endogenous and microbial biomarkers
324 for periodontitis and type 2 diabetes mellitus. Front Endocrinol (Lausanne). 14:1292596. doi:
325 10.3389/fendo.2023.1292596.
- 326 [7] Gao Chenyi., Iles Mark., Larvin Harriet., Bishop David Timothy., Bunce David., Ide Mark.,
327 Sun Fanyiwen., Pavitt Susan., Wu Jianhua., Kang Jing. Genome-wide association studies on
328 periodontitis: A systematic review. PLoS One,2024 September 6;19(9):1-23.
329 doi:10.1371/journal.pone.0306983.
- 330 [8] Radaic A, Kapila YL.(2021) The oralome and its dysbiosis: New insights into oral
331 microbiome-host interactions. Computational and Structural Biotechnology Journal,19:1335-1360.
332 doi: 10.1016/j.csbj.2021.02.010.
- 333 [9] Hajjishengallis G, Chavakis T, Lambris JD.(2020) Current understanding of periodontal
334 disease pathogenesis and targets for host-modulation therapy. Periodontol 2000,84(1):14-34. doi:
335 10.1111/prd.12331.
- 336 [10] Ana G, Sánchez-Medrano, Rita E, Martínez-Martinez, Ruth, Soria-Guerra, Diana,

- 337 Portales-Perez, Horacio, Bach, Fidel, Martinez-Gutierrez. A systematic review of the protein
338 composition of whole saliva in subjects with healthy periodontium compared with chronic
339 periodontitis. *PLoS One*, 2023 May, 18(5):1-12. doi:10.1371/journal.pone.0286079.
- 340 [11] Di Paola R, Mazzon E, Muià C, Crisafulli C, Terrana D, Greco S, Britti D, Santori D, Oteri
341 G, Cordasco G, Cuzzocrea S.(2007) Effects of etanercept, a tumour necrosis factor-alpha
342 antagonist, in an experimental model of periodontitis in rats. *British Journal of*
343 *Pharmacology*,150(3):286-97. doi: 10.1038/sj.bjp.0706979.
- 344 [12] Eskan MA, Jotwani R, Abe T, Chmelar J, Lim JH, Liang S, Ciero PA, Krauss JL, Li F,
345 Rauner M, Hofbauer LC, Choi EY, Chung KJ, Hashim A, Curtis MA, Chavakis T, Hajishengallis
346 G.(2012) The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss.
347 *Nature Immunology*,13(5):465-73. doi: 10.1038/ni.2260.
- 348 [13] Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris
349 JD.(2016).Complement therapeutics in inflammatory diseases: promising drug candidates for
350 C3-targeted intervention. *Molecular Oral Microbiology*, 31(1):3-17. doi: 10.1111/omi.12129
- 351 [14] Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello
352 RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC,
353 Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD.(2018)
354 Safety profile after prolonged C3 inhibition. *Clinical Immunology*,197:96-106. doi:
355 10.1016/j.clim.2018.09.004.
- 356 [15] Ricklin D, Mastellos DC, Reis ES, Lambris JD.(2018) The renaissance of complement
357 therapeutics. *Nature Reviews Nephrology*,14(1):26-47. doi: 10.1038/nrneph.2017.156.
- 358 [16] Minaldi E, Cahill K.(2023) Recent Updates in Understanding NSAID Hypersensitivity. *Curr*
359 *Allergy Asthma Rep*,23(3):181-188. doi: 10.1007/s11882-023-01064-3.
- 360 [17] Szeto CC, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, Chen CH, Park JB, Tam
361 LS, Vareesangthip K, Tsoi KKF, Chan FKL.(2020) Non-steroidal anti-inflammatory drug
362 (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal
363 comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.*Gut*,
364 69(4):617-629. doi: 10.1136/gutjnl-2019-319300.
- 365 [18] Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ,
366 Timpson NJ, Higgins JPT, Dimou N, Langenberg C, Loder EW, Golub RM, Egger M, Davey
367 Smith G, Richards JB.(2021) Strengthening the reporting of observational studies in epidemiology
368 using mendelian randomisation (STROBE-MR): explanation and elaboration. *British Medical*
369 *Journal*, 375:n2233. doi: 10.1136/bmj.n2233.
- 370 [19] Yu X, Liu S. Identifying potential drug targets for myocardial infarction through Mendelian
371 randomization. *PLoS One*. 2024 Dec 23;19(12):e0313770. doi: 10.1371/journal.pone.0313770.
- 372 [20] Qi T, Song L, Guo Y, Chen C, Yang J.(2024) From genetic associations to genes: methods,
373 applications, and challenges. *Trends in Genetics*,40(8):642-667. doi: 10.1016/j.tig.2024.04.008.
- 374 [21] Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R,
375 Karlsson A, Santos R, Overington JP, Hingorani AD, Casas JP.(2017) The druggable genome and
376 support for target identification and validation in drug development. *Science Translational*
377 *Medicine*, 9(383):eaag1166. doi: 10.1126/scitranslmed.aag1166.
- 378 [22] Zhang C, He Y, Liu L.(2024) Identifying therapeutic target genes for migraine by systematic
379 druggable genome-wide Mendelian randomization.*The Journal of Headache and Pain*. 2024 Jun
380 12;25(1):100. doi: 10.1186/s10194-024-01805-3.

- 381 [23] Vösa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al.(2021) Large-scale
382 cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate
383 blood gene expression. *Nature Genetics*, 53(9):1300-1310. doi: 10.1038/s41588-021-00913-z.
- 384 [24] Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al.(2023)
385 FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature*,
386 613(7944):508-518. doi: 10.1038/s41586-022-05473-8.
- 387 [25] 1000 Genomes Project Consortium; Auton A, Brooks LD, Durbin RM, Garrison EP, Kang
388 HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR.(2015) A global reference
389 for human genetic variation. *Nature*, 526(7571):68-74. doi: 10.1038/nature15393.
- 390 [26] Greco M FD, Minelli C, Sheehan NA, Thompson JR.(2015) Detecting pleiotropy in
391 Mendelian randomisation studies with summary data and a continuous outcome. *Statistics in*
392 *Medicine*,34(21):2926-40. doi: 10.1002/sim.6522.
- 393 [27] Bowden J, Holmes MV.(2019) Meta-analysis and Mendelian randomization: A review. *Res*
394 *Synth Methods*,10(4):486-496. doi: 10.1002/jrsm.1346.
- 395 [28] Gudicha DW, Schmittmann VD, Vermunt JK.(2017) Statistical power of likelihood ratio and
396 Wald tests in latent class models with covariates. *Behav Res Methods*, 49(5):1824-1837. doi:
397 10.3758/s13428-016-0825-y.
- 398 [29] Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP,
399 Kutalik Z, Holmes MV, Minelli C, Morrison JV, Pan W, Relton CL, Theodoratou E.(2023)
400 Guidelines for performing Mendelian randomization investigations: update for summer 2023.
401 *Wellcome Open Research*, 4:186. doi: 10.12688/wellcomeopenres.15555.3.
- 402 [30] Glickman ME, Rao SR, Schultz MR.(2014) False discovery rate control is a recommended
403 alternative to Bonferroni-type adjustments in health studies. *Journal of Clinical Epidemiology*,
404 67(8):850-7. doi: 10.1016/j.jclinepi.2014.03.012.
- 405 [31] Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard
406 ME, Wray NR, Visscher PM, Yang J.(2016) Integration of summary data from GWAS and eQTL
407 studies predicts complex trait gene targets. *Nature Genetics*. 2016 May;48(5):481-7. doi:
408 10.1038/ng.3538.
- 409 [32] Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V.
410 (2014)Bayesian test for colocalisation between pairs of genetic association studies using summary
411 statistics. *PLoS Genetics*, 10(5):e1004383. doi: 10.1371/journal.pgen.1004383.
- 412 [33] Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, Jansen R, de Geus EJ, Boomsma
413 DI, Wright FA, Sullivan PF, Nikkola E, Alvarez M, Civelek M, Lusi AJ, Lehtimäki T, Raitoharju
414 E, Kähönen M, Seppälä I, Raitakari OT, Kuusisto J, Laakso M, Price AL, Pajukanta P, Pasaniuc
415 B.(2016) Integrative approaches for large-scale transcriptome-wide association studies. *Nature*
416 *Genetics*, 48(3):245-52. doi: 10.1038/ng.3506.
- 417 [34] Liu L, Yan R, Guo P, Ji J, Gong W, Xue F, Yuan Z, Zhou X.(2024) Conditional
418 transcriptome-wide association study for fine-mapping candidate causal genes. *Nature*
419 *Genetics*,56(2):348-356. doi: 10.1038/s41588-023-01645-y.
- 420 [35] Zhou W, Bi W, Zhao Z, Dey KK, Jagadeesh KA, Karczewski KJ, Daly MJ, Neale BM, Lee
421 S.(2022) SAIGE-GENE+ improves the efficiency and accuracy of set-based rare variant
422 association tests. *Nature Genetics*, 54(10):1466-1469. doi: 10.1038/s41588-022-01178-w.
- 423 [36] Chen J, Qin S, Liu S, Zhong K, Jing Y, Wu X, Peng F, Li D, Peng C.(2023) Targeting matrix
424 metalloproteases in diabetic wound healing. *Frontiers in Immunology*, 14:1089001. doi:

- 425 10.3389/fimmu.2023.1089001.
- 426 [37] Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC. Classical macrophage
427 activation up-regulates several matrix metalloproteinases through mitogen activated protein
428 kinases and nuclear factor- κ B. *PLoS One*. 2012;7(8):e42507. doi: 10.1371/journal.pone.0042507.
- 429 [38] Grenier D, Grignon L.(2006) Response of human macrophage-like cells to stimulation by
430 *Fusobacterium nucleatum* ssp. *nucleatum* lipopolysaccharide. *Oral Microbiology Immunology*,
431 21(3):190-6. doi: 10.1111/j.1399-302X.2006.00278.x.
- 432 [39] Hernández M, Dutzan N, García-Sesnich J, Abusleme L, Dezerega A, Silva N, González FE,
433 Vernal R, Sorsa T, Gamonal J.(2011) Host-pathogen interactions in progressive chronic
434 periodontitis. *Journal of Dental Research*, 90(10):1164-70. doi: 10.1177/0022034511401405.
- 435 [40] Emingil G, Kuula H, Sorsa T, Atilla G.(2006) Gingival crevicular fluid matrix
436 metalloproteinase-25 and -26 levels in periodontal disease. *Journal of Periodontology*,
437 77(4):664-71. doi: 10.1902/jop.2006.050288.
- 438 [41] Kuula H, Salo T, Pirilä E, Hagström J, Luomanen M, Gutierrez-Fernandez A, Romanos GE,
439 Sorsa T.(2008) Human beta-defensin-1 and -2 and matrix metalloproteinase-25 and -26 expression
440 in chronic and aggressive periodontitis and in peri-implantitis. *Archives of Oral Biology*,
441 53(2):175-86. doi: 10.1016/j.archoralbio.2007.09.010.
- 442 [42] Leroy C, Belkina NV, Long T, Deruy E, Dissous C, Shaw S, Tulasne D.(2016) Caspase
443 Cleavages of the Lymphocyte-oriented Kinase Prevent Ezrin, Radixin, and Moesin
444 Phosphorylation during Apoptosis. *Journal of Biological Chemistry*, 291(19):10148-61. doi:
445 10.1074/jbc.M116.721365.
- 446 [43] Hong H, Xu G, Bao G, Zhang J, Chen C, Chen J, Wu C, Jiang J, Huang J, Huang H, Cui
447 Z.(2024) VIRMA promotes neuron apoptosis via inducing m6A methylation of STK10 in spinal
448 cord injury animal models. *CNS Neuroscience & Therapeutics*, 30(3):e14453. doi:
449 10.1111/cns.14453.
- 450 [44] Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I.(2010) Cdc25 phosphatases
451 are required for timely assembly of CDK1-cyclin B at the G2/M transition. *Journal of Biological*
452 *Chemistry*, 285(22):16978-90. doi: 10.1074/jbc.M109.096552.
- 453 [45] Goebel EJ, Corpina RA, Hinck CS, Czepnik M, Castonguay R, Grenha R, Boisvert A,
454 Miklossy G, Fullerton PT, Matzuk MM, Idone VJ, Economides AN, Kumar R, Hinck AP,
455 Thompson TB.(2019) Structural characterization of an activin class ternary receptor complex
456 reveals a third paradigm for receptor specificity. *Proceedings of the National Academy of*
457 *Sciences of the United States of America*, 116(31):15505-15513. doi: 10.1073/pnas.1906253116.
- 458 [46] Jeon J, Lee H, Jeon MS, Kim SJ, Choi C, Kim KW, Yang DJ, Lee S, Bae YS, Choi WI, Jung
459 J, Eyun SI, Yang S.(2023) Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by
460 Non-Amplification of Activin A-ACVR2B-NOX4 Axis Pathway. *Advanced Science (Weinheim*
461 *Baden-Wuerttemberg, Germany)*, 10(14):e2205161. doi: 10.1002/advs.202205161.
- 462



medRxiv preprint doi: <https://doi.org/10.1101/2025.01.19.25320804>; this version posted January 20, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1. Flowchart of the design of this study.




Figure 2. Mendelian randomisation results of druggable genes with CP.

medRxiv preprint doi: <https://doi.org/10.1101/2025.01.19.25320804>; this version posted January 20, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 3. Results of MR studies of the full phenotypic range of MMP25.